 Health Canada has approved Puma Biotechnology Incs NASDAQ: PBYI Nerlynx neratinib in combination with capecitabine for metastatic HER2-overexpressedamplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. Knight Therapeutics Inc OTC: KHTRF has the exclusive right to commercialize Nerlynx in Canada. 